SCHEMBL6674568

SCHEMBL6674568

COC(=O)c1cc(/C=C/c2ccccc2)ccc1NC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.65
KMT2A Q03164 5/20 0.65
CHEK1 O14757 1/20 0.62
PIM1 P11309 1/20 0.62
MAPK8 P45983 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
MAPK1 P28482 2/20 0.58
HSD17B10 Q99714 2/20 0.58
ALDH1A1 P00352 7/20 0.56
PDE5A O76074 1/20 0.54
PDE4D Q08499 2/20 0.54
TNFRSF1A P19438 1/20 0.53
PKM P14618 2/20 0.53
CYP1A2 P05177 2/20 0.52
CYP1A1 P04798 1/20 0.52
CYP1B1 Q16678 1/20 0.52
HPGD P15428 5/20 0.51
MEN1 O00255 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
POLB P06746 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674576 1.00 KDM4E (0.65) KDM4EKMT2ACHEK1PIM1MAPK8
SCHEMBL6677116 0.92 CHEK1 (0.70) KDM4EKMT2ACHEK1PIM1MAPK8
SCHEMBL6675681 0.92 CHEK1 (0.70) KDM4EKMT2ACHEK1PIM1MAPK8
SCHEMBL6676947 0.87 KDM4E (0.60) KDM4EKMT2AMAPK1HSD17B10ALDH1A1
SCHEMBL6678169 0.87 KDM4E (0.60) KDM4EKMT2AMAPK1HSD17B10ALDH1A1
SCHEMBL7643669 0.84 MEN1 (0.60) KDM4EKMT2AMAPK1HSD17B10ALDH1A1
SCHEMBL7643672 0.84 MEN1 (0.60) KDM4EKMT2AMAPK1HSD17B10ALDH1A1
SCHEMBL266327 0.82 CHEK1 (0.80) KDM4EKMT2ACHEK1PIM1MAPK8
SCHEMBL22887373 0.82 CYP1A2 (0.63) KDM4EKMT2AMAPK1HSD17B10ALDH1A1
SCHEMBL22887376 0.82 CYP1A2 (0.63) KDM4EKMT2AMAPK1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US claimed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP disclosed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 KDM4E 3079/4885KMT2A 3788/4885CHEK1 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.